Significant delay in the introduction of systemic treatment of moderate to severe psoriasis: a prospective multicentre observational study in outpatients from hospital dermatology departments in France

被引:30
|
作者
Maza, A. [1 ]
Richard, M. A. [2 ]
Aubin, F. [3 ]
Ortonne, J. P. [4 ]
Prey, S. [5 ,6 ]
Bachelez, H. [7 ]
Beylot-Barry, M. [5 ,6 ]
Bulai-Livideanu, C. [1 ]
Lahfa, M. [1 ]
Nougue, J. [8 ]
Mengual, X. [9 ]
Le Moigne, M. [1 ]
Lauwers-Cances, V. [10 ]
Paul, C. [1 ]
机构
[1] Univ Toulouse 3, Serv Dermatol, Hop Larrey, UMR CNRS INSERM 1056 5165, F-31062 Toulouse, France
[2] Aix Marseille Univ, UMR 911, Inserm CRO2, F-13385 Marseille, France
[3] Univ Franche Comte, F-25030 Besancon, France
[4] CHU Nice, Hop Archet 2, Serv Dermatol, Nice, France
[5] CHU Bordeaux, EA 2406, Serv Dermatol, F-33000 Bordeaux, France
[6] Univ Bordeaux Segalen, F-33000 Bordeaux, France
[7] Hop St Louis, Serv Dermatol, F-75475 Paris, France
[8] Ctr Hosp Montauban, Serv Dermatol, Montauban, France
[9] Statitec, Labege, France
[10] CHU Toulouse, Serv Epidemiol, Toulouse, France
关键词
PHASE-III TRIAL; PATIENT-MEMBERSHIP SURVEY; QUALITY-OF-LIFE; DOUBLE-BLIND; ALEXITHYMIA; IMPACT; ADALIMUMAB; DEPRESSION; EFFICACY; BURDEN;
D O I
10.1111/j.1365-2133.2012.10991.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background There is a low rate of systemic treatment usage in moderate to severe psoriasis. Objectives The primary objective of the present study was to assess the time period between lack of control of moderate to severe psoriasis with topical treatment or phototherapy as perceived by patients and the medical decision to introduce a systemic treatment. Methods This was a prospective multicentre study, which included patients with moderate to severe psoriasis. A standardized questionnaire was completed by physicians and patients at the time the decision was taken to introduce a systemic treatment. The primary outcome was the duration of uncontrolled psoriasis, as estimated by the patient, prior to the introduction of systemic treatment. Factors associated with a delay in systemic treatment defined as > 2 years of uncontrolled psoriasis were assessed. The agreement between patients and physicians on the duration of uncontrolled psoriasis was estimated. Results The study included 142 patients. The mean age was 48 years, the mean Psoriasis Area and Severity index (PASI) was 18.5 and the mean Dermatology Life Quality Index (DLQI) was 12. The median duration of uncontrolled psoriasis estimated by patients and physicians was 3 years and 2 years, respectively. Factors associated with a delay in the introduction of systemic treatment as assessed by patients were fewer than three physician visits since psoriasis was uncontrolled [odds ratio (OR) 3.05; 95% confidence interval (CI) 1.29-7.21], Hospital Anxiety and Depression (HAD) scale < 10 (OR 2.83; 95% CI 1.19-6.71), continuous psoriasis evolution (OR 2 67; 95% CI 1.12-6.42), low consumption of topical treatment (OR 2.35; 95% CI 1.03-5.34). Conclusions There is a significant delay in the introduction of systemic treatment in moderate to severe psoriasis. Patients with low level anxiety and limited use of healthcare resources appear to be at higher risk of experiencing long delays.
引用
收藏
页码:643 / 648
页数:6
相关论文
共 25 条
  • [1] Management of moderate to severe psoriasis with systemic immunomodulatory therapies: a 5-year experience from two departments of dermatology of Northern France
    Staumont-Salle, D.
    Florin, V.
    Cottencin, A. C.
    Chaby, G.
    Delaporte, E.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2012, 26 (08) : 1038 - 1039
  • [2] The risk of mild, moderate and severe infections in IBD patients: results from a prospective, multicentre, observational cohort study - PRIQ
    Ardabili, A. Rezazadeh
    van Esser, D.
    Wintjens, D.
    Cilissen, M.
    Deben, D.
    Mujagic, Z.
    Russ, F.
    Stassen, L.
    van Bodegraven, A.
    Wong, D.
    Winkens, B.
    Jonkers, D.
    Romberg-Camps, M.
    Pierik, M.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 631 - 633
  • [3] The Real-World Burden of Moderate-to-Severe Psoriasis in Patients Under Systemic Treatment from Baltic Countries: Data from the CRYSTAL Observational Study
    Eisen, Maigi
    Hartmane, Ilona
    Kingo, Kulli
    Mikazans, Ingmars
    Toomson, Tiina
    Toomela, Karin
    Valiukeviciene, Skaidra
    MEDICINA-LITHUANIA, 2025, 61 (03):
  • [4] Persistence with biological therapies for the treatment of moderate-to-severe psoriasis: a prospective observational study from the British Association of Dermatologists' Biologic Interventions Register (BADBIR)
    Warren, R.
    Smith, C.
    Yiu, Z.
    Ashcroft, D.
    Barker, J.
    Burden, D.
    Lunt, M.
    McElhone, K.
    Ormerod, A.
    Owen, C.
    Reynolds, N.
    Griffiths, C.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 171 (06) : E118 - E119
  • [5] Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study
    Elnabawi, Youssef A.
    Dey, Amit K.
    Goyal, Aditya
    Groenendyk, Jacob W.
    Chung, Jonathan H.
    Belur, Agastya D.
    Rodante, Justin
    Harrington, Charlotte L.
    Teague, Heather L.
    Baumer, Yvonne
    Keel, Andrew
    Playford, Martin P.
    Sandfort, Veit
    Chen, Marcus Y.
    Lockshin, Benjamin
    Gelfand, Joel M.
    Bluemke, David A.
    Mehta, Nehal N.
    CARDIOVASCULAR RESEARCH, 2019, 115 (04) : 721 - 728
  • [6] Baseline characteristics according to previous exposure to systemic treatment in patients with moderate to severe psoriasis: Results from the PROSE study
    Augustin, Matthias
    Dauden, Esteban
    Mrowietz, Ulrich
    Paul, Carle
    Rissler, Michael
    Gathmann, S.
    Sieder, Christian
    Bachuber, Teresa
    Orsenigo, Roberto
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB175 - AB175
  • [7] Differential persistence of four biological therapies for the treatment of moderate-to-severe psoriasis: a prospective observational cohort study from the British Association of Dermatologists' Biologic Interventions Register
    Warren, R.
    Smith, C.
    Yiu, Z.
    Ashcroft, D.
    Barker, J.
    Burden, D.
    Lunt, M.
    McElhone, K.
    Ormerod, A.
    Owen, C.
    Reynolds, N.
    Griffiths, C. E. M.
    BRITISH JOURNAL OF DERMATOLOGY, 2015, 173 : 11 - 12
  • [8] Enhanced Effectiveness of Adalimumab Compared to Topical/Traditional Systemic Agents in the Treatment of Moderate to Severe Plaque Psoriasis: Results from a Canadian Observational Epidemiologic Study (COMPLETE-PS)
    Charles W. Lynde
    Maryam S. Alam
    Kamal Ohson
    Angélique Gagné-Henley
    Miriam Avadisian
    Ronald B. Vender
    Dermatology and Therapy, 2022, 12 : 921 - 931
  • [9] Enhanced Effectiveness of Adalimumab Compared to Topical/Traditional Systemic Agents in the Treatment of Moderate to Severe Plaque Psoriasis: Results from a Canadian Observational Epidemiologic Study (COMPLETE-PS)
    Lynde, Charles W.
    Alam, Maryam S.
    Ohson, Kamal
    Gagne-Henley, Angelique
    Avadisian, Miriam
    Vender, Ronald B.
    DERMATOLOGY AND THERAPY, 2022, 12 (04) : 921 - 931
  • [10] Drug survival of conventional systemic and biologic therapies for moderate-to-severe psoriasis in clinical practice in Spain: prospective results from the SAHARA study
    Puig, Luis
    Carrascosa, Jose-Manuel
    Dauden, Esteban
    Sulleiro, Sara
    Guisado, Cristina
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2020, 31 (04) : 344 - 351